Up­dat­ed: Bio­gen chops cer­tain stroke and RNA ther­a­py pro­grams as it con­tin­ues R&D re­vamp

Bio­gen plans to scrap three clin­i­cal pro­grams and “de­pri­or­i­tize” pre­clin­i­cal gene ther­a­py and oph­thal­mol­o­gy pro­grams as part of CEO Chris Viehbach­er’s larg­er strat­e­gy to over­haul R&D, cut costs and move away from high-risk neu­ro­science drug de­vel­op­ment.

The Cam­bridge, MA-based biotech said Tues­day morn­ing dur­ing its first-quar­ter earn­ings call that it has ex­it­ed oph­thal­mol­o­gy re­search and is “re-fo­cus­ing in­vest­ment in gene ther­a­py to ad­vance fun­da­men­tal tech­nol­o­gy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER